Updated Results of Rituximab Pre- and Post-BEAM with or without 90 Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Jad ChahoudIssa F Khouri

Abstract

Purpose: We evaluated the effect on long-term survival of adding rituximab (R) to BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning with or without yttrium-90 ibritumomab tiuxetan (90YIT) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) undergoing autologous stem cell transplant (ASCT).Experimental design: Patients were enrolled on three consecutive phase II clinical trials. Patients received two doses of rituximab (375 and 1,000 mg/m2) during mobilization of stem cells, followed by 1,000 mg/m2 on days +1 and +8 after ASCT with R-BEAM or 90YIT-R-BEAM (90YIT dose of 0.4 mCi/kg) conditioning.Results: One hundred thirteen patients were enrolled, with 73 receiving R-BEAM and 40 receiving 90YIT-R-BEAM. All patients had a prior exposure to rituximab. The median follow-up intervals for survivors were 11.8, 8.1, and 4.2 years in the three trials, respectively. The 5-year disease-free survival (DFS) rates were 62% for R-BEAM and 65% for 90YIT-R-BEAM (P = 0.82). The 5-year overall survival rates were 73% and 77%, respectively (P = 0.65). In patients with de novo DLBCL, survival outcomes of the germinal center/activated b-cell histologic subtypes were similar with 5-year OS rates (P = 0.52) and DFS rates ...Continue Reading

References

Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Apr 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J C ByrdI W Flinn
Apr 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S M O'BrienM J Keating
Apr 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Issa F KhouriRichard E Champlin
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
Nov 29, 2008·The New England Journal of Medicine·G LenzUNKNOWN Lymphoma/Leukemia Molecular Profiling Project
Aug 27, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·William W L ChoiWing C Chan
Apr 16, 2010·The New England Journal of Medicine·Georg Lenz, Louis M Staudt
Jul 28, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christian GisselbrechtNorbert Schmitz
Sep 29, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Catherine ThieblemontChristian Gisselbrecht
Oct 19, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Nicolas MounierUNKNOWN Lymphoma Working Party of European Blood and Marrow Transplantation Registry (EBMT)
Aug 1, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Matthew MeiAmrita Y Krishnan
Apr 28, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ginna G LaportUNKNOWN Blood and Marrow Transplant Clinical Trials Network
Dec 17, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Issa F KhouriPadmanee Sharma

❮ Previous
Next ❯

Citations

Nov 6, 2018·Bone Marrow Transplantation·Parastoo B DahiSergio A Giralt
Aug 13, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Issa F KhouriRichard E Champlin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Related Papers

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Matthew MeiAmrita Krishnan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Amrita KrishnanStephen J Forman
© 2022 Meta ULC. All rights reserved